森田疗法结合右佐匹克隆对抑郁伴失眠患者睡眠质量及神经递质水平的影响

Effect of Morita Therapy Combined with Eszopiclone on Sleep Quality and Neurotransmitter Levels in Patients with Depression and Insomnia

目的:探讨森田疗法结合右佐匹克隆对抑郁伴失眠患者睡眠质量及神经递质水平的影响。方法:回顾性选取2020年8月—2023年8月在赣州市第三人民医院睡眠科收治的156例抑郁伴失眠患者作为研究对象,根据治疗方案分为药物组(n=74)和联合组(n=82)。两组均进行抗抑郁治疗,药物组给予右佐匹克隆药物进行治疗,联合组在药物组的基础上联合森田疗法。对比两组患者临床疗效、抑郁程度[汉密尔顿抑郁量表(HAMD)评分、抑郁量表(CES-D)]、睡眠指标[匹兹堡睡眠质量指数(PSQI)、阿森斯失眠评定量表(AIS)、总睡眠时间]、相关神经递质[P物质(SP)、神经肽Y(NPY)、5-羟色胺(5-HT)、γ-氨基丁酸(γ-GABA)]、生活满意度指数A(LSIA)、幸福感指数量表(IWB)评分。结果:联合组的总有效率(82.93%)显著高于药物组的总有效率(66.22%)(P<0.05)。两组治疗2个月的HAMD、CES-D、PSQI、AIS、SP、IWB均低于治疗前,总睡眠时间均长于治疗前,NPY、5-HT、γ-GABA、LSIA均高于治疗前;联合组的HAMD、CES-D、PSQI、AIS、SP、IWB均低于药物组,总睡眠时间长于对照组,NPY、5-HT、γ-GABA、LSIA均高于药物组(P<0.05)。结论:森田疗法结合右佐匹克隆可以提高抑郁伴失眠患者的临床疗效,增加睡眠时间,改善睡眠质量,调节神经递质水平,提高生活满意度和幸福感程度。

Objective:To investigate the effect of Morita therapy combined with Eszopiclone on sleep quality and neurotransmitter levels in patients with depression and insomnia.Method:A total of 156 patients with depression and insomnia admitted to the Sleep Department of Ganzhou Third People's Hospital from August 2020 to August 2023 were retrospectively selected as the research objects.According to the treatment plan,they were divided into drug group(n=74)and combined group(n=82).Both groups were treated with antidepressants.The drug group was treated with Eszopiclone,and the combined group was treated with Morita therapy on the basis of the drug group.The clinical efficacy,depression degree[Hamilton depression scale(HAMD)score,depression scale(CES-D)],sleep index[Pittsburgh sleep quality index(PSQI),Athens insomnia scale(AIS),total sleep time],related neurotransmitters[substance P(SP),neuropeptide Y(NPY),5-hydroxytryptamine(5-HT),γ-aminobutyric acid(γ-GABA)],life satisfaction index A(LSIA)and index of well-being(IWB)scores were compared between the two groups.Result:The total effective rate of the combined group(82.93%)was significantly higher than that of the drug group(66.22%)(P<0.05).The HAMD,CES-D,PSQI,AIS,SP and IWB of the two groups after 2 months of treatment were lower than those before treatment,and the total sleep time were longer than those before treatment,NPY,5-HT,γ-GABA and LSIA were higher than those before treatment;the HAMD,CES-D,PSQI,AIS,SP and IWB in the combined group were lower than those in the drug group,and the total sleep time was longer than that in the drug group,NPY,5-HT,γ-GABA and LSIA were higher than those in the drug group(P<0.05).Conclusion:Morita therapy combined with Eszopiclone can improve the clinical efficacy of patients with depression and insomnia,increase sleep time,improve sleep quality,regulate neurotransmitter levels,and improve life satisfaction and happiness.